The anticoagulant effect of prolame, N-(3-hydroxy-1,3,5(10)estratrien-17 beta-yl)-3-hydroxypropylamine, a novel amino-estrogen.
The anticoagulant and estrogenic effects of prolame, N-(3-hydroxy-1,3,5(10)-estratrien-17 beta-yl)-3-hydroxypropylamine, are described. A single subcutaneous injection of prolame in male mice, ovariectomized mice, adult and infant male rats, produced dose-dependent increases of blood clotting time, which could be observed with the larger doses even after 4 days. In ovariectomized mice, prolame produced vaginal cornifications of shorter duration than those produced by estradiol-17 beta. The evidence suggests that, in contrast with currently used estrogens, prolame would not generate cardiovascular accidents if used for the treatment of prostatic carcinoma; it could also be exceptionally effective for the prevention of thrombosis.
D000818:Animals; D000925:Anticoagulants; D003029:Coagulants / Q000494:pharmacology; D003292:Convulsants / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D045166:Estradiol Congeners; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors; D014621:Vagina / Q000187:drug effects
D000925:Anticoagulants; D003029:Coagulants; D003292:Convulsants; D045166:Estradiol Congeners; D004963:Estrenes; C047867:prolame